
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suppository containing phenytoin sodium, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing phenytoin are listed in capsule, injection, tablet and suspension forms. No finished phenytoin product of any kind is listed in suppository form.
Suppository bases differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Phenytoin is an anticonvulsant (seizure medicine) that a pharmacy may compound, including as topical preparations, when a prescriber orders it.
Phenytoin is a hydantoin anticonvulsant, used as phenytoin and as its sodium salt. It is thought to calm overactive nerve cells by blocking sodium channels, which limits the rapid, repeated firing that lets a seizure spread. Manufactured products include Dilantin extended phenytoin sodium capsules, Dilantin Infatabs chewable tablets and Dilantin-125 oral suspension, indicated for tonic-clonic and psychomotor (temporal lobe) seizures; the capsules and Infatabs are also indicated for seizures during or after neurosurgery. Phenytoin sodium injection is indicated for generalized tonic-clonic status epilepticus, seizures during neurosurgery, and short-term substitution for oral phenytoin. Compounding literature describes topical phenytoin formulations for skin and mucosal wounds, which is not an FDA-approved indication. A prescriber might order phenytoin compounded in a form or vehicle that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
The phenytoin sodium injection label carries a boxed warning: infusing it into a vein too quickly can cause severe low blood pressure and heart rhythm problems, so it is given slowly with heart monitoring. Phenytoin labels also warn of serious skin reactions (including Stevens-Johnson syndrome and DRESS), liver injury, blood disorders, suicidal thoughts, and seizures if it is stopped suddenly. Do not use it if you are allergic to phenytoin or other hydantoins, have had liver injury from phenytoin, or take delavirdine. Phenytoin interacts with many drugs, including azole antifungals, warfarin and valproate, and MedlinePlus notes it can make hormonal birth control less reliable. It may harm an unborn baby. LactMed states that needing phenytoin is not a reason to stop breastfeeding. Good oral hygiene lowers the risk of gum overgrowth. Do not stop it on your own, and talk to your prescriber or pharmacist about side effects.
Phenytoin is thought to act by voltage-dependent blockade of neuronal sodium channels, reducing sustained high-frequency repetitive firing. StatPearls describes it as about 90% bound to plasma proteins, mainly albumin, with only unbound drug active; binding may be lower in hypoalbuminemia, uremia, pregnancy and neonates. Metabolism is hepatic, mainly CYP2C9 and to a lesser extent CYP2C19, and is saturable, so small dose increases can raise serum levels disproportionately. The Dilantin capsule label gives an oral half-life averaging 22 hours (range 7 to 42). Peak levels occur 4 to 12 hours after Dilantin capsules and 1.5 to 3 hours after Infatabs or Dilantin-125. Phenytoin is a potent hepatic enzyme inducer. StatPearls notes intramuscular absorption is erratic. The injection is contraindicated in sinus bradycardia, sino-atrial block, second and third degree AV block and Adams-Stokes syndrome. The label notes HLA-B*1502 and CYP2C9*3 carriers may face higher SJS/TEN risk. Topical phenytoin for dermal and mucosal wounds appears in compounding literature (IJPC) and is not an FDA-approved indication. Dosing is per prescriber. Monitor serum levels, interpreting total levels against albumin when binding is altered, and watch blood counts, liver function and mood.
Wash your hands. If the suppository is soft, chill it in its wrapper in the refrigerator or under cool water for a few minutes, then unwrap it. For rectal use, coat the tip with a water-soluble lubricant (not petroleum jelly), lie on your side with your upper knee bent, and insert it pointed end first past the muscle at the opening. For vaginal use, lie on your back with knees bent and insert it as far as it comfortably goes, by finger or applicator; bedtime use limits leakage, and a panty liner protects clothing. Stay lying down about 15 minutes. Wash your hands.
Suppositories are nonaqueous, so under USP <795> they can carry a beyond-use date of up to 180 days at controlled room temperature or in the refrigerator when no other stability data apply. Storage depends on the base: fatty bases can soften at room temperature and may be labeled for the refrigerator, while polyethylene glycol bases usually do not need refrigeration. Keep them cool so they do not melt, and refrigerate them if your label says to.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Insert 1 unwrapped suppository